Menu
IPO

Kantipur Pharmaceuticals Lab to Launch IPO from Mangsir 10, Targeting Local Residents and Nepali Migrant Workers

Rohan PoudelBy Rohan Poudel•

Kantipur Pharmaceuticals Lab Limited is poised to make its debut on the Nepal Stock Exchange with an Initial Public Offering (IPO) commencing from Mangsir 10, 2080 (approximately November 26, 2023). This significant move marks a new chapter for the company and presents a fresh investment avenue within Nepal's expanding pharmaceutical industry. The IPO is strategically designed to engage specific investor demographics: local residents of areas affected by the company's operations and Nepalis residing and working abroad.

The company plans to issue 800,000 units of shares, each priced at NPR 100, exclusively for local residents within its project-affected zone. This allocation constitutes 10% of Kantipur Pharmaceuticals Lab's total issued capital, which stands at NPR 800 million. The specific beneficiaries of this allocation are residents of Panchkhal Municipality Ward No. 7 in Kavrepalanchok District, an area directly influenced by the company's activities. This practice is a cornerstone of Nepali IPO regulations, ensuring that communities directly impacted by industrial projects also partake in their economic benefits.

Furthermore, in an effort to broaden participation and encourage investment from the diaspora, Kantipur Pharmaceuticals Lab will also issue 90,000 units of shares, also at NPR 100 per share, to Nepalis employed overseas. This segment represents 10% of the shares earmarked for the general public, aligning with national policies aimed at channeling remittances into productive domestic capital market investments. This quota offers a unique opportunity for non-resident Nepalis to contribute to and benefit from the growth of a local enterprise.

Prospective investors from the local project-affected areas can apply for a minimum of 10 units and a maximum of 10,000 units. For Nepalis working abroad, the application range is set from a minimum of 10 units to a maximum of 7,000 units. The application period for local residents will open on Mangsir 10 and is scheduled to close on Mangsir 24 at the earliest, with a potential extension until Poush 13 if the quota remains undersubscribed. Nepalis working abroad have a shorter application window, with the deadline set for Mangsir 15, though this may also be extended to Mangsir 24 if the allocated shares are not fully subscribed.

Muktinath Capital Limited has been appointed as the official issue manager for this IPO. Local residents can conveniently submit their applications through designated branches of Muktinath Bikas Bank and Sindhu Bikas Bank located in Banepa and Panchkhal. A nominal fee of NPR 2 will be charged for the application form. Nepalis working abroad can leverage the C-ASBA system via the 'Mero Share' online platform or through any ASBA member bank and financial institution approved by the Nepal Securities Board, ensuring a streamlined application process.

From a financial assessment standpoint, CARE Ratings Nepal has assigned Kantipur Pharmaceuticals Lab an 'CARE-NP Double B Plus Issuer Rating'. This rating signifies a moderate level of risk concerning the company's ability to fulfill its financial obligations. Investors are advised to consider this rating as a crucial component of their investment analysis, understanding that while the company's foundational aspects appear robust, all investments inherently carry a degree of risk.

The company's financial projections also provide valuable insights for potential investors. The simple payback period for an investment in Kantipur Pharmaceuticals Lab is estimated at 4.50 years, with the discounted payback period extending to 5.71 years. These metrics offer an indication of the time horizon for capital recovery. Furthermore, the company reports a Net Present Value (NPV) of NPR 1,599,866,758 and an Internal Rate of Return (IRR) of 24.27%. These figures, if realized, suggest a potentially attractive return on investment. Nepal's pharmaceutical sector has demonstrated consistent expansion, fueled by increasing health consciousness, an aging demographic, and governmental support for domestic manufacturing. Kantipur Pharmaceuticals Lab's entry into the public market is poised to further invigorate this vital sector, offering investors a compelling opportunity to engage with a growing segment of the Nepali economy.

Rohan Poudel

Rohan Poudel

Rohan is a Full Stack Developer and the technical architect behind Nepali Share Market. With expertise in React, Node.js, and Machine Learning, he specializes in building scalable financial platforms and automated trading algorithms for the NEPSE ecosystem.

View Full Profile